CymaBay Therapeutic (CBAY) PT Raised to $22 at Oppenheimer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to CymaBay Therapeutic (CBAY) PT Raised to $22 at Oppenheimer

CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis

September 7, 2023 7:00 AM EDT

Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p... More

CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023

September 6, 2023 4:05 PM EDT

NEWARK, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday, September 7 at 8:00 a.m. ET to share topline results from the Phase 3 pivotal RESPONSE study of seladelpar in patients with primary biliary cholangitis (PBC).

... More